| Name | Bemnifosbuvir hemisulfate |
| Description | Bemnifosbuvir hemisulfate (AT-527) is a potent inhibitor of HCV virus replication. |
| In vitro | The potent in vitro activity of AT-511, the free base of bemnifosbuvir hemisulfate, against several coronaviruses, including SARS-CoV-2. In normal human airway epithelial cells, the concentration of AT-511 required to inhibit replication of SARS-CoV-2 by 90% (EC90) was 0.47?μM, very similar to its EC90 against human coronavirus (HCoV)-229E, HCoV-OC43, and SARS-CoV in Huh-7 cells[1]. |
| In vivo | When given orally to rats and monkeys, bemnifosbuvir hemisulfate preferentially delivered high levels of AT-9010 in the liver in vivo.These favorable preclinical attributes support bemnifosbuvir hemisulfate may increase SVR rates[2]. |
| Storage | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 5 mg/mL (3.96 mM), Sonication is recommended. DMSO : 170 mg/mL (134.8 mM), Sonication is recommended.
|
| Keywords | SARS-CoV-2 | SARS-CoV | SARSCoV | SARS coronavirus | phosphoramidate | pangenotypic | nucleotide | Inhibitor | inhibit | Hepatitis C virus | HCVProtease | HCV Protease | HCV | guanosine | Bemnifosbuvir hemisulfate | Bemnifosbuvir | AT527 | AT 527 | antiviral |
| Inhibitors Related | Methyl 2-amino-5-bromobenzoate | Sofosbuvir | Deferiprone | Ribavirin | Molnupiravir | Silymarin | Hydroxychloroquine | Ritonavir | Chloroquine phosphate | α-Cyclodextrin | Artemisinin | Dexamethasone |
| Related Compound Libraries | Bioactive Compound Library | Anti-Viral Compound Library | Drug Repurposing Compound Library | Inhibitor Library | NO PAINS Compound Library | Orally Active Compound Library | Clinical Compound Library | Bioactive Compounds Library Max | Covalent Inhibitor Library | Anti-Infection Compound Library | Anti-COVID-19 Compound Library | Nucleotide Compound Library |